ClinicalTrials.gg
RecruitingNCT06692140SORT OUT XIIUpdated Oct 22, 2026

Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention

An interventional study of Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s) and PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s)) in Ischemia, Myocardial, Coronary Artery Disease and Percutaneous Coronary Intervention (PCI), sponsored by Odense University Hospital. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionCoronary Artery DiseaseRegistry: Myocardial IschemiaReclassifiedWhy we changed it
Registry
Myocardial Ischemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Myocardial Ischemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Coronary Artery Disease by Odense University Hospital — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Odense University Hospital.

Planned enrollment
Largest of 11
3,150 · median 104
Started
2024
the only one that year
No phase
10 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Coronary Artery Disease by Odense University Hospital, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 14th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 14 studies in Coronary Artery Disease by Odense University Hospital is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Coronary Artery Disease by Odense University Hospital, or all of them as a file.
02

Study summary

The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention

03

Conditions studied

  • Ischemia, Myocardial
  • Coronary Artery Disease
  • Percutaneous Coronary Intervention (PCI)

Browse trials for

Keywords

  • Drug-eluting stent
  • outcome
04

In context

Coronary Artery Disease Reclassified

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's planned enrollment of 3,150 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Not able to consent to study participating (eg. intubated patients)
  • Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study
  • Do not speak Danish
  • Already included in the SORT OUT XII study
  • \<1 year
  • Allergic to study related treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,150 participants (estimated)

Study arms

  • Experimental
    Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent

    Percutaneous coronary interventin with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent

    Device: Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

  • Active comparator
    Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)

    Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)

    Device: PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

Interventions

  • DeviceUltra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

    Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

  • DevicePCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

    Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

07

What researchers measure

Primary outcomes

  1. Number of patients with target lesion failure

    Target lesion failure (TLF) is a composite of cardiac death, myocardial infarction (not clearly attributable to a non-intervention lesion) or target lesion revascularization with percutaneous coronary intervention or coronary artery bypass operation

    Time frame: 1 year

Secondary outcomes

  1. Number of patients with all-cause death

    All-cause death is defined as any death

    Time frame: 1 year, 3 years and 5 years

  2. Number of patients with cardiac death

    Cardiac death is defined as death resulting from cardiovascular causes: death caused by acute myocardial infarction, death caused by sudden cardiac, including unwitnessed, death, death resulting from heart failure, death caused by cardiovascular procedures. Undetermined cause of death is defined as a death not attributable to any other category because of the absence of any relevant source documents. Such deaths will be classified as cardiovascular for end point determination

    Time frame: 1 year, 3 years and 5 years

  3. Number of patients with myocardial infarction

    Myocardial infarction diagnosis follows "The Joint ESC/ACCF/AHA/WHF Task Force on "Third Universal Definition of acute myocardial infarction",which has been adapted by Academy Research Consortium. Acute myocardial infarction not related to other than index lesion is defined as any acute myocardial infarction that is not clearly attributable to a non-target vessel

    Time frame: 1 year, 3 years and 5 years

  4. Number of patients with definite stent thrombosis

    Definite stent thrombosis is defined as: Angiographic confirmation of stent thrombosis. The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent or in a side branch originating from the stented segment and the presence of at least one of the following criteria: Acute onset of ischemic symptoms at rest New electrocardiographic changes suggestive of acute ischemia Typical rise and fall in cardiac biomarkers (refer to definition of spontaneous myocardial infarction) Or Pathological confirmation of stent thrombosis

    Time frame: 1 year, 3 years and 5 years

  5. Number of patients with probable stent thrombosis

    Probable stent thrombosis is defined as any myocardial infarction that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause regardless of the time after the index procedure,

    Time frame: 1 year, 3 years and 5 years

  6. Number of patients with target lesion revascularization

    Target lesion revascularization is defined as a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment including the 5-mm margin proximal and distal to the stent

    Time frame: 1 year, 3 years and 5 years

  7. Number of patients with target vessel revascularization

    Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel including the target lesion. The target vessel is defined as the entire major intervened coronary vessel, including side branches

    Time frame: 1 year, 3 years and 5 years

08

Study locations

3 of 3 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — IPD used in the results publication

Supporting information: Study protocol

Time frame: 12. NOV 2024 til the end of the study

Access criteria: On request

Data sharing details ↗ · www.clinicaltrials.gov

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2028, 43 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 43 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 18, 2024
StartActual
Nov 16, 2024
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2032
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Aalborg University Hospital · Aalborg, DenmarkContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • Aarhus University Hospital · Aarhus, DenmarkContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • Odense University Hospital · Odense, DenmarkContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Aalborg University Hospital · Aalborg, DenmarkContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • Aarhus University Hospital · Aarhus, DenmarkContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • Odense University Hospital · Odense, DenmarkContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    + 4 other changes: identifiers, verification date, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06692140
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Nov 16, 2024
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2032 (estimated)
Last update
Oct 22, 2026

Study contacts

Lisette O Jensen, MD
Contact
lisette.okkels.jensen@rsyd.dk
+4565412690
Lisette O Jensen
principal investigator · Odense University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion